Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 156 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Compass Pathways PLC 주요 수익원은 American Infrastructure Corporation이며, 최신 수익 발표에서 수익은 174,738입니다. 지역별로는 United States이 Compass Pathways PLC의 주요 시장이며, 수익은 383,234입니다.
Compass Pathways PLC은 수익성이 있나요?
no, 최신 재무제표에 따르면 Compass Pathways PLC의 순손실은 $0입니다.